QTTB Q32 Bio Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 5, 2026
$8,23
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$1,9152 haftanın en düşüğü
$23,5752 haftanın en yükseği
Piyasa Değeri (MRQ)
$195M
P/E
3.4
Hisse Başına Kâr
$2.42
Gelir
$54M
rozetleriniz
52 Haftlık Aralık
$2–$24
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$40
P/E
3.4
ROE
200.3%
Net Kâr Marjı
55.5%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
QTTB Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$8.23
Piyasa Değeri (MRQ)
$195M
P/E
3.4
Hisse Başına Kâr
$2.42
Gelir
$54M
ROE
200.3%
52 Haftlık Aralık
$2–$24
QTTB Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 26 Mart 2024 | 1-for-18 | Ters |
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$54M2018-12-31 → 2025-12-31
Hisse Başına Kâr$2.422021-12-31 → 2025-12-31
Serbest Nakit Akışı$-34M2018-12-31 → 2025-12-31
Net kar marjı55.5%2018-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | QTTB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | 3.45Y ort. ≈-57.8 | ≈-57.8 | · | · | |
| P/S (F/S) | 2.05Y ort. ≈172.5 | ≈172.5 | 8.2 | Düşük değerli | |
| F/D (MRQ) | 1.85Y ort. ≈9.5 | ≈9.5 | 2.3 | Daha pahalı | |
| Price / FCF (Fiyat / Serbest Nakit Akışı) | -3.25Y ort. ≈-11.7 | ≈-11.7 | · | · | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | -3.25Y ort. ≈-11.9 | ≈-11.9 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 2.55Y ort. ≈10.2 | ≈10.2 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | QTTB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Operating Margin (Faaliyet Kâr Marjı) | 31.4%5Y ort. ≈-1468.5% | ≈-1468.5% | -312.3% | En üst düzey | |
| EBITDA Margin (FAVÖK Marjı) | 31.4%5Y ort. ≈-1468.5% | ≈-1468.5% | -312.3% | En üst düzey | |
| Pretax Margin (Vergi Öncesi Kar Marjı) | 55.5% | · | -1.3% | En üst düzey | |
| Net Profit Margin (Net Kâr Marjı) | 55.5%5Y ort. ≈-127.5% | ≈-127.5% | -351.2% | En üst düzey | |
| ROA | 38.7%5Y ort. ≈-18.1% | ≈-18.1% | -34.5% | En üst düzey | |
| ROE | 200.3%5Y ort. ≈-63.1% | ≈-63.1% | -36.9% | En üst düzey | |
| ROIC | 40.2%5Y ort. ≈-385.1% | ≈-385.1% | 16.0% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | QTTB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 20.35Y ort. ≈7.2 | ≈7.2 | 6.8 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 4.35Y ort. ≈4.2 | ≈4.2 | 5.3 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | QTTB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 155.9% | · | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 81.8% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | QTTB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.75Y ort. ≈0.2 | ≈0.2 | 0.3 | En üst düzey | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$2.4M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
110.2%
Sonraki Rapor
Kas 11, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 4, 2026 | $-0.43 | $-0.55 | 22.2% |
| 31 Mart 2026 | May 7, 2026 | $-0.54 | $-0.69 | 22.1% |
| 31 Aralık 2025 | $3.65 | $-0.88 | 515.8% | |
| 30 Eylül 2025 | $-0.60 | $-1.21 | 50.5% | |
| 30 Haziran 2025 | $-0.78 | $-1.00 | 22.0% | |
| 31 Mart 2025 | $-0.90 | $-1.25 | 28.3% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | $0 | $-7M | $3M | $34M | $3M | $2M | $5M | |
| R&D Expense | $19M | $48M | $32M | $98M | $93M | $100M | $89M | $48M | |
| SG&A Expense | $18M | $18M | $10M | $38M | $37M | $33M | $22M | $17M | |
| Operating Expenses | $37M | $66M | $42M | $136M | $130M | $133M | $112M | $65M | |
| Operating Income | $17M | $-66M | $-48M | $-133M | $-96M | $-130M | $-110M | $-60M | |
| Other Non-op | $1M | $4M | $1M | $134M | $185.0K | $2M | $6M | $4M | |
| Pretax Income | $30M | $-46M | $-53M | $1M | $-96M | · | · | · | |
| Income Tax | $0 | $21.0K | $318.0K | $715.0K | $0 | $0 | $0 | $0 | |
| Net Income | $30M | $-48M | $-54M | $-5M | $-96M | $-129M | $-104M | $-56M | |
| EPS (Basic) | $2.42 | $-5.12 | $-153.96 | $-0.09 | $-1.73 | · | · | · | |
| EPS (Diluted) | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 | · | · | · | |
| Shares (Basic) | 12,300,568 | 9,320,884 | 349,060 | 57,399,762 | 55,283,318 | · | · | · | |
| Shares (Diluted) | 12,314,796 | 9,657,696 | 349,060 | 57,399,762 | 55,283,318 | · | · | · | |
| EBITDA | $17M | $-66M | · | $-133M | $-96M | $-130M | $-110M | $-62M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $78M | $26M | $34M | $108M | $217M | $54M | $38M | |
| Short-term Investments | · | $0 | $0 | $141M | · | · | · | · | |
| Prepaid Expense | $7M | $4M | $3M | $6M | $7M | $2M | $4M | $7M | |
| Other Current Assets | $20.0K | $396.0K | $83.0K | · | · | · | · | · | |
| Current Assets | $55M | $82M | $29M | $181M | $192M | $220M | $267M | $222M | |
| PP&E (Net) | $979.0K | $1M | $2M | $1M | $2M | $37M | $43M | $36M | |
| PP&E (Gross) | $3M | $3M | $3M | $7M | $8M | $53M | $51M | $38M | |
| Accum. Depreciation | $2M | $1M | $966.0K | $6M | $6M | $16M | $8M | $2M | |
| Other Non-current Assets | $0 | $116.0K | $5M | · | · | · | · | · | |
| Total Assets | $62M | $92M | $47M | $228M | $212M | $264M | $311M | $259M | |
| Accounts Payable | $879.0K | $3M | $3M | $1M | $2M | $5M | $3M | $16M | |
| Accrued Liabilities | $4M | $7M | $10M | · | · | · | · | · | |
| Current Liabilities | $11M | $16M | $14M | $23M | $17M | $23M | $12M | $23M | |
| Capital Leases | $5M | $6M | $6M | $28M | $24M | $13M | · | · | |
| Other Non-current Liabilities | $0 | $55M | $55M | · | · | · | · | · | |
| Total Liabilities | $20M | $87M | $119M | $50M | $42M | $68M | $52M | $63M | |
| Common Stock | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K | $5.0K | $4.0K | $3.0K | |
| Paid-in Capital | $247M | $240M | $4M | $608M | · | · | · | · | |
| Retained Earnings | $-205M | $-235M | $-187M | $-429M | $-424M | $-328M | $-200M | $-96M | |
| AOCI | · | $0 | $0 | $-404.0K | $-7.0K | $0 | $183.0K | $-77.0K | |
| Stockholders' Equity | $42M | $6M | $-183M | $-131M | $170M | $196M | $259M | $196M | |
| Liabilities + Equity | $62M | $92M | $47M | $228M | $212M | $264M | $311M | $259M | |
| Shares Outstanding | 12,858,047 | 12,197,615 | 359,569 | 57,483,910 | 57,150,274 | 50,265,575 | 45,116,742 | 37,358,526 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $5M | $4M | $1M | $13M | $17M | $13M | $8M | $3M | |
| Deferred Tax | · | $100.0K | $300.0K | · | · | · | · | · | |
| Restructuring | · | · | $10M | · | · | · | · | · | |
| Operating Cash Flow | $-34M | $-68M | $-19M | $-114M | $-110M | $-94M | $-91M | $-43M | |
| CapEx | $0 | $75.0K | $5.0K | $1M | $2M | $4M | $22M | $25M | |
| Investing Cash Flow | $7M | $20M | $-5.0K | $37M | $-51M | $205M | $-52M | $-122M | |
| Stock Issued | $0 | $42M | $0 | $0 | $50M | · | $135M | · | |
| Net Stock Activity | $0 | $42M | · | $0 | $50M | · | $135M | · | |
| Financing Cash Flow | $-3M | $95M | $406.0K | $596.0K | $52M | $53M | $158M | $151M | |
| Net Change in Cash | · | · | $5M | $-76M | $-108M | $164M | $15M | $-13M | |
| Free Cash Flow | $-34M | $-68M | · | $-115M | $-112M | $-98M | $-113M | $-68M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 31.4% | · | · | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1671.1% | |
| Net Margin | 55.5% | · | · | -156.0% | -281.9% | -4762.9% | -6237.4% | -1553.1% | |
| Pretax Margin | 55.5% | · | · | 37.3% | · | · | · | · | |
| EBITDA Margin | 31.4% | · | · | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1671.1% | |
| ROA | 38.7% | -68.5% | · | -2.3% | -40.3% | -44.8% | -36.5% | -28.8% | |
| ROE | 200.3% | -398.3% | · | -2.6% | -52.0% | -70.3% | -40.2% | -28.0% | |
| ROIC | 40.2% | -1165.3% | · | -30.2% | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.0 | · | 8.0 | 11.1 | 9.7 | 21.5 | 8.7 | |
| Quick Ratio | 4.3 | 4.7 | · | 1.5 | 6.3 | 9.6 | 4.3 | 1.5 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.0 | · | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.27 | $0.47 | · | $3.10 | $2.97 | $3.90 | $5.73 | $5.21 | |
| Revenue / Share | $4.36 | $0.00 | · | $0.06 | · | · | · | · | |
| Cash Flow / Share | $-2.72 | $-7.01 | · | $-1.98 | · | · | · | · | |
| Cash / Share | $3.76 | $6.39 | · | $0.59 | $1.90 | $4.33 | $1.19 | $1.02 | |
| EPS (TTM) | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -90.6% | 1157.2% | · | · | · | |
| Revenue CAGR 3Y | 155.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 81.8% | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $54M | $0 | $-7M | $3M | $34M | $3M | $2M | $5M | |
| Net Income TTM | $30M | $-48M | $-54M | $-5M | $-96M | $-129M | $-104M | $-56M | |
| Market Cap | $43M | $42M | · | $1.30B | $3.74B | $10.21B | $16.81B | $15.04B | |
| P/E | 1.4 | -0.5 | -0.1 | -252.0 | -37.9 | · | · | · | |
| P/S | 0.8 | · | · | 406.4 | 110.2 | 3780.5 | 10090.3 | 2825.3 | |
| P/B | 1.0 | 7.4 | · | 7.3 | 22.1 | 52.1 | 65.0 | 77.2 | |
| P / Tangible Book | 1.0 | 7.4 | · | · | 22.1 | 52.1 | · | · | |
| P / Cash Flow | -1.3 | -0.6 | · | -11.5 | -34.1 | -108.3 | -184.0 | -353.3 | |
| P / FCF | -1.3 | -0.6 | · | -11.3 | -33.4 | -104.2 | -148.5 | -222.8 | |
| Earnings Yield | 72.9% | -191.3% | -1406.8% | -0.40% | -2.6% | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-15M | $2M | $3M | $3M | $802.0K | $802.0K | |
| R&D Expense | $4M | $3M | $3M | $4M | $5M | $7M | $11M | $14M | $13M | $10M | $8M | $7M | $8M | $8M | $27M | $26M | |
| SG&A Expense | $5M | $5M | $5M | $4M | $4M | $5M | $4M | $4M | $5M | $5M | $3M | $2M | $2M | $2M | $8M | $8M | |
| Operating Expenses | $9M | $8M | $8M | $8M | $9M | $12M | $15M | $19M | $18M | $15M | $11M | $10M | $10M | $10M | $35M | $34M | |
| Operating Income | $-9M | $-8M | $46M | $-8M | $-9M | $-12M | $-15M | $-19M | $-18M | $-15M | $-26M | $-8M | $-7M | $-7M | $-34M | $-33M | |
| Other Non-op | $319.0K | $113.0K | $115.0K | $188.0K | $-318.0K | $1M | $358.0K | $1M | $2M | $158.0K | $196.0K | $84.0K | $165.0K | $578.0K | $1M | $1M | |
| Pretax Income | · | · | $58M | $-7M | $-9M | $-11M | $-14M | $-18M | $-16M | $1M | $-27M | $-14M | $-6M | $-7M | $-33M | $-32M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $21.0K | $0 | $0 | $0 | $383.0K | $-65.0K | $0 | $0 | $-403.0K | $46.0K | |
| Net Income | $-9M | $-8M | $58M | $-7M | $-9M | $-11M | $-14M | $-18M | $-17M | $1M | $-27M | $-14M | $-6M | $-7M | $-34M | $-34M | |
| EPS (Basic) | $-0.44 | $-0.54 | $4.70 | $-0.60 | $-0.78 | $-0.90 | $-3.27 | $-1.46 | $-1.42 | $1.03 | $-76.91 | $-40.52 | $-16.69 | $-19.84 | $-0.60 | $-0.59 | |
| EPS (Diluted) | $-0.44 | $-0.54 | $4.70 | $-0.60 | $-0.78 | $-0.90 | $2.63 | $-1.46 | $-1.42 | $-6.33 | $-76.91 | $-40.52 | $-16.69 | $-19.84 | $-0.58 | $-0.59 | |
| Shares (Basic) | 20,342,345 | 14,095,371 | · | 12,240,542 | 12,197,615 | 12,197,615 | · | 12,076,412 | 11,964,224 | 995,280 | · | 346,288 | 347,936 | 344,623 | · | 57,447,192 | |
| Shares (Diluted) | 20,342,345 | 14,095,371 | · | 12,240,542 | 12,197,615 | 12,197,615 | · | 12,076,412 | 11,964,224 | 2,334,180 | · | 346,288 | 347,936 | 344,623 | · | 57,447,192 | |
| EBITDA | $-9M | $-8M | · | $-8M | $-9M | $-12M | · | $-19M | $-18M | $-15M | · | $-31M | $-31M | $-28M | · | $-33M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $106M | $51M | $48M | $49M | $55M | $65M | $78M | $89M | $98M | $116M | $26M | $29M | $77M | $39M | $34M | $43M | |
| Short-term Investments | · | · | · | · | · | · | · | $0 | · | · | $0 | $74M | $50M | $111M | · | · | |
| Prepaid Expense | $3M | $6M | $7M | $2M | $3M | $3M | $4M | $5M | $4M | $3M | $3M | $3M | $4M | $4M | $6M | $12M | |
| Other Current Assets | $19.0K | $20.0K | $20.0K | $24.0K | $77.0K | $93.0K | $396.0K | $229.0K | $51.0K | $67.0K | $83.0K | · | · | · | · | · | |
| Current Assets | $110M | $57M | $55M | $51M | $58M | $69M | $82M | $94M | $112M | $138M | $29M | $107M | $131M | $154M | $181M | $213M | |
| PP&E (Net) | $804.0K | $889.0K | $979.0K | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $0 | $845.0K | $1M | $1M | $1M | |
| PP&E (Gross) | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $0 | $7M | $7M | $7M | $8M | |
| Accum. Depreciation | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $966.0K | $0 | $7M | $6M | $6M | $7M | |
| Other Non-current Assets | · | · | $0 | $0 | $570.0K | $444.0K | $116.0K | $40.0K | $1M | $1M | $5M | · | · | · | · | · | |
| Total Assets | $116M | $64M | $62M | $58M | $66M | $79M | $92M | $105M | $124M | $152M | $47M | $140M | $169M | $198M | $228M | $263M | |
| Accounts Payable | $2M | $653.0K | $879.0K | $973.0K | $910.0K | $3M | $3M | $1M | $2M | $5M | $3M | $8M | $3M | $4M | $1M | $5M | |
| Accrued Liabilities | $4M | $4M | $4M | $4M | $4M | $5M | $7M | $9M | $11M | $20M | $10M | · | · | · | · | · | |
| Current Liabilities | $5M | $11M | $11M | $11M | $12M | $15M | $16M | $14M | $17M | $33M | $14M | $25M | $23M | $19M | $23M | $25M | |
| Capital Leases | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $27M | $27M | $27M | $28M | $28M | |
| Other Non-current Liabilities | · | · | $0 | $55M | $55M | $55M | $55M | $55M | $55M | $55M | $55M | · | · | · | · | · | |
| Total Liabilities | $10M | $17M | $20M | $76M | $78M | $83M | $87M | $86M | $91M | $104M | $119M | $52M | $50M | $46M | $50M | $54M | |
| Common Stock | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Paid-in Capital | $327M | $259M | $247M | $244M | $243M | $242M | $240M | $239M | $237M | $235M | $4M | $614M | $612M | $610M | · | · | |
| Retained Earnings | $-222M | $-213M | $-205M | $-263M | $-255M | $-246M | $-235M | $-221M | $-203M | $-186M | $-187M | $-526M | $-493M | $-458M | $-429M | $-395M | |
| AOCI | · | · | · | $0 | $0 | $0 | · | $-1.0K | $-1.0K | $-5.0K | $0 | $-36.0K | $-88.0K | $-182.0K | $-404.0K | $-457.0K | |
| Stockholders' Equity | $106M | $46M | $42M | $-18M | $-12M | $-4M | $6M | $18M | $34M | $49M | $-183M | $88M | $119M | $152M | $178M | $209M | |
| Liabilities + Equity | $116M | $64M | $62M | $58M | $66M | $79M | $92M | $105M | $124M | $152M | $47M | $140M | $169M | $198M | $228M | $263M | |
| Shares Outstanding | 23,736,600 | 14,629,463 | 12,858,047 | 12,304,352 | 12,197,615 | 12,197,615 | 12,197,615 | 12,138,869 | 11,995,206 | 11,929,520 | 359,569 | 57,902,210 | 57,798,133 | 57,794,767 | 57,483,910 | 57,480,610 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $417.0K | $521.0K | $-4M | $-2M | $296.0K | $3M | $3M | |
| Restructuring | · | · | · | $0 | $0 | $900.0K | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-3M | $-6M | $-6M | $-4M | $-11M | $-12M | $-11M | $-20M | $-22M | $-15M | $-11M | $42M | $2M | $-12M | $-27M | $-25M | |
| CapEx | · | · | $0 | $0 | · | · | $2.0K | $58.0K | $15.0K | $0 | $0 | $-223.0K | $-224.0K | $5.0K | $9.0K | $6.0K | |
| Investing Cash Flow | $0 | $0 | $7M | $0 | $0 | $0 | $-2.0K | $10M | $10M | $97.0K | $0 | $-92M | $-31M | $-5.0K | $18M | $-108M | |
| Stock Issued | $0 | $10M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $42M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | $10M | · | · | · | $0 | · | · | · | $42M | · | · | · | · | · | · | |
| Financing Cash Flow | $59M | $9M | $-2M | $-2M | · | · | $317.0K | $997.0K | $-6M | $99M | $76.0K | $178.0K | $-120.0K | $15.0K | $32.0K | $124.0K | |
| Net Change in Cash | · | · | · | · | · | · | · | · | · | · | · | $-48M | $37M | $5M | $-9M | $-133M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-15M | · | · | · | $-26M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 3706.5% | 4021.9% | · | 3444.1% | 3229.2% | 3296.0% | · | · | · | · | · | · | -8705.1% | -3430.3% | · | -4097.5% | |
| Net Margin | 3636.6% | 3963.0% | · | 3358.6% | 3341.2% | 2973.3% | · | · | · | · | · | · | -9899.4% | -3596.5% | · | -4205.2% | |
| Pretax Margin | · | · | · | 3358.6% | 3341.2% | 2973.3% | · | · | · | · | · | · | -8278.2% | -3247.1% | · | -3939.3% | |
| EBITDA Margin | 3706.5% | 4021.9% | · | 3444.1% | 3229.2% | 3296.0% | · | · | · | · | · | · | -8705.1% | -3430.3% | · | -4097.5% | |
| ROA | -9.8% | -10.7% | · | -9.1% | -10.0% | -9.5% | · | -14.4% | -11.6% | 0.59% | · | -16.4% | -15.4% | -11.3% | · | -13.7% | |
| ROE | -19.1% | -36.0% | · | 9658.8% | -89.2% | -49.3% | · | -33.0% | -22.2% | 1.0% | · | -22.2% | -19.5% | -13.8% | · | -16.6% | |
| ROIC | · | · | · | 41.1% | 75.0% | 304.6% | · | -102.8% | -53.5% | -30.4% | · | -35.1% | -25.8% | -18.1% | · | -15.7% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 20.3 | 5.4 | · | 4.6 | 5.1 | 4.7 | · | 6.5 | 6.5 | 4.2 | · | 4.2 | 5.7 | 8.3 | · | 8.4 | |
| Quick Ratio | 19.7 | 4.8 | · | 4.4 | 4.8 | 4.5 | · | 6.2 | 5.7 | 3.5 | · | 4.1 | 5.5 | 8.1 | · | 1.7 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | -0.0 | -0.0 | · | -0.0 | -0.0 | -0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.46 | $3.17 | · | $-1.50 | $-1.00 | $-0.33 | · | $1.51 | $2.79 | $4.09 | · | $1.52 | $2.07 | $2.63 | · | $3.64 | |
| Revenue / Share | $-0.01 | $-0.01 | · | $-0.02 | $-0.02 | $-0.03 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.01 | $0.01 | · | $0.01 | |
| Cash Flow / Share | · | $-0.45 | · | · | · | $-1.02 | · | · | · | $-6.23 | · | · | · | $-0.45 | · | · | |
| Cash / Share | $4.48 | $3.47 | · | $3.99 | $4.50 | $5.37 | · | $7.34 | $8.14 | $9.68 | · | $0.50 | $1.33 | $0.68 | · | $0.75 | |
| EPS (TTM) | $3.12 | $2.78 | · | $0.35 | $-0.51 | $-1.15 | · | $-86.12 | $-125.18 | $-140.45 | · | $-77.63 | $-37.70 | $-21.52 | · | $-0.14 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $-15M | $-13M | $-10M | · | $9M | $8M | $5M | · | $3M | |
| Net Income TTM | $34M | $33M | · | $-42M | $-52M | $-60M | · | $-61M | $-57M | $-46M | · | $-61M | $-81M | $-104M | · | $-4M | |
| Market Cap | $302M | $94M | · | $24M | $18M | $20M | · | $542M | $215M | $203M | · | $1.22B | $921M | $1.07B | · | $1.67B | |
| P/E | 4.1 | 2.3 | · | 5.7 | -2.9 | -1.4 | · | -0.5 | -0.1 | -0.1 | · | -0.3 | -0.4 | -0.9 | · | -207.0 | |
| P/S | · | · | · | · | · | · | · | -36.9 | -16.8 | -21.2 | · | 138.4 | 118.7 | 200.2 | · | 519.3 | |
| P/B | 2.9 | 2.0 | · | -1.3 | -1.5 | -5.0 | · | 29.6 | 6.4 | 4.2 | · | 13.8 | 7.7 | 7.1 | · | 8.0 | |
| P / Tangible Book | 2.9 | 2.0 | · | · | · | · | · | 29.6 | 6.4 | 4.2 | · | 13.8 | 7.7 | 7.1 | · | 8.0 | |
| P / Cash Flow | · | -14.8 | · | · | · | -1.6 | · | · | · | -14.0 | · | · | · | -41.1 | · | · | |
| Earnings Yield | 24.5% | 43.3% | · | 17.7% | -34.2% | -69.7% | · | -193.0% | -697.4% | -824.2% | · | -368.6% | -236.7% | -116.1% | · | -0.48% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $54M | $0 | $-7M | $3M | $34M |
| Faaliyet Kâr Marjı % | 31.4% | · | · | -4154.6% | -282.4% |
| Net Gelir | $30M | $-48M | $-54M | $-5M | $-96M |
| Seyreltilmiş Hisse Başı Kâr | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 4.9 | 5.0 | · | 8.0 | 11.1 |
| Cari Oran | 4.3 | 4.7 | · | 1.5 | 6.3 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-34M | $-68M | · | $-115M | $-112M |
Kurumsal Sahipler (13F) 75 dosya · $283.7M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
75
Tutulan Değer
$283.7M
Yeni pozisyonlar
29
Çıkan pozisyonlar
8
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 29 (+18 önceki Ç'ye göre) | 8 (0 önceki Ç'ye göre) | 17 (+3 önceki Ç'ye göre) | 14 (+5 önceki Ç'ye göre) | +13.0M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | $52.590.554 | 4.127.987 | 18,53% | Hisse senetleri |
| Boxer Capital Management, LLC | $40.122.209 | 3.149.310 | 14,14% | Hisse senetleri |
| Atlas Venture Life Science Advisors, LLC | $34.615.930 | 2.717.106 | 12,20% | Hisse senetleri |
| BVF INC/IL | $29.939.000 | 2.350.000 | 10,55% | Hisse senetleri |
| RA CAPITAL MANAGEMENT, L.P. | $29.715.502 | 2.332.457 | 10,47% | Hisse senetleri |
| Point72 Asset Management, L.P. | $14.949.065 | 1.173.396 | 5,27% | Hisse senetleri |
| Opaleye Management Inc. | $11.860.940 | 931.000 | 4,18% | Hisse senetleri |
| Logos Global Management LP | $10.192.000 | 800.000 | 3,59% | Hisse senetleri |
| SummitTX Capital, L.P. | $9.348.281 | 733.774 | 3,29% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.609.550 | 518.803 | 2,33% | Hisse senetleri |
| Ikarian Capital, LLC | $5.478.200 | 430.000 | 1,93% | Hisse senetleri |
| Woodline Partners LP | $3.646.341 | 286.212 | 1,29% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $3.474.860 | 272.752 | 1,22% | Hisse senetleri |
| Sanofi | $3.109.617 | 244.083 | 1,10% | Hisse senetleri |
| ACORN CAPITAL ADVISORS, LLC | $2.754.019 | 216.171 | 0,97% | Hisse senetleri |
| Ikarian Capital, LLC | $2.548.000 | 200.000 | 0,90% | Satım opsiyonu |
| RENAISSANCE TECHNOLOGIES LLC | $2.288.104 | 179.600 | 0,81% | Hisse senetleri |
| JANE STREET GROUP, LLC | $2.073.396 | 162.747 | 0,73% | Hisse senetleri |
| MONIMUS CAPITAL MANAGEMENT, LP | $1.682.139 | 132.036 | 0,59% | Hisse senetleri |
| BOOTHBAY FUND MANAGEMENT, LLC | $1.661.640 | 130.427 | 0,59% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $1.563.506 | 122.690 | 0,55% | Hisse senetleri |
| CITADEL ADVISORS LLC | $1.537.247 | 120.663 | 0,54% | Hisse senetleri |
| BlackRock, Inc. | $1.509.780 | 118.507 | 0,53% | Hisse senetleri |
| VANGUARD GROUP INC | $1.065.889 | 321.051 | 0,38% | Hisse senetleri |
| MARSHALL WACE, LLP | $854.153 | 67.045 | 0,30% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $843.605 | 66.217 | 0,30% | Hisse senetleri |
| BOOTHBAY FUND MANAGEMENT, LLC | $780.962 | 61.300 | 0,28% | Satım opsiyonu |
| Carlyle Group Inc. | $769.020 | 60.363 | 0,27% | Hisse senetleri |
| STATE STREET CORP | $665.206 | 52.214 | 0,23% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $631.675 | 49.582 | 0,22% | Hisse senetleri |
| Quadrature Capital Ltd | $463.685 | 36.396 | 0,16% | Hisse senetleri |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $440.970 | 34.613 | 0,16% | Hisse senetleri |
| DAFNA Capital Management LLC | $419.095 | 32.896 | 0,15% | Hisse senetleri |
| Knott David M Jr | $387.449 | 30.412 | 0,14% | Hisse senetleri |
| Affinity Asset Advisors, LLC | $353.879 | 27.777 | 0,12% | Hisse senetleri |
| Squarepoint Ops LLC | $303.085 | 23.790 | 0,11% | Hisse senetleri |
| NORTHERN TRUST CORP | $301.059 | 23.631 | 0,11% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $300.511 | 23.588 | 0,11% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $297.377 | 23.342 | 0,10% | Hisse senetleri |
| MANGROVE PARTNERS IM, LLC | $282.191 | 22.150 | 0,10% | Hisse senetleri |
| LPL Financial LLC | $231.486 | 18.170 | 0,08% | Hisse senetleri |
| UBS Group AG | $191.202 | 15.008 | 0,07% | Hisse senetleri |
| Balyasny Asset Management L.P. | $157.237 | 12.342 | 0,06% | Hisse senetleri |
| ExodusPoint Capital Management, LP | $144.421 | 11.336 | 0,05% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $139.223 | 10.928 | 0,05% | Hisse senetleri |
| XTX Topco Ltd | $138.535 | 10.874 | 0,05% | Hisse senetleri |
| MORGAN STANLEY | $82.259 | 6.456 | 0,03% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $61.458 | 4.824 | 0,02% | Hisse senetleri |
| FMR LLC | $43.163 | 3.388 | 0,02% | Hisse senetleri |
| CITIGROUP INC | $36.793 | 2.888 | 0,01% | Hisse senetleri |
Aktivistler ve %5+ sahipler 4 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VII LLC, OrbiMed Genesis GP LLC ×5 başvurular | 20 Temmuz 2026 | 13,90% | Değişiklik | · | SEC |
| Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, L.P., Atlas Venture Associates Opportunity II, LLC, Atlas Venture Opportunity Fund Ill, L.P., Atlas Venture Associates Opportunity III, L.P., Atlas Venture Associates Opportunity III, LLC ×2 başvurular | 28 Mayıs 2026 | 3,60% | Değişiklik | · | SEC |
| Acorn Bioventures, L.P., Acorn Capital Advisors, GP, LLC, Anders Hove | 04 Nisan 2024 | · | İlk başvuru | M&A / satış | SEC |
| Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield Management Company, L.P., James E. Flynn ×5 başvurular | 01 Mayıs 2020 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 29 içeriden öğrenenler · 13 yöneticiler · 18 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Jodie Pope Morrison | CEO | 16 Temmuz 2026 A | 353.104 | 0 | 2 | $-122.502 |
| Albert Seymour | President and Chief Executive Officer | 06 Eylül 2023 M | 150.874 | 0 | 0 | $0 |
| Lee Kalowski | CFO and President | 16 Temmuz 2026 A | 142.443 | 0 | 2 | $-49.406 |
| Paul Alloway | Former President and Chief Operating Officer of Homology Medicines, Inc. | 25 Mart 2024 S | 2.596 | 0 | 0 | $0 |
| Timothy P Kelly | Chief Operating Officer | 24 Şubat 2022 A | 2.224 | 0 | 0 | $0 |
| Siyamak Rasty | Chief Operating Officer | 09 Temmuz 2019 S | 222.707 | 0 | 0 | $0 |
| Shelia M. Violette | Chief Scientific Officer | 16 Temmuz 2026 A | 130.569 | 0 | 1 | $-12.696 |
| Jason Campagna | Chief Medical Officer | 24 Şubat 2025 A | 37.500 | 0 | 0 | $0 |
| Charles Michaud Jr | Former Vice President, Corporate Controller and Treasurer of Homology Medicines, Inc. | 25 Mart 2024 S | 927 | 0 | 0 | $0 |
| Julie Jordan | Chief Medical Officer | 03 Ağustos 2023 M | 7.496 | 0 | 0 | $0 |
| Michael Lee Blum | Chief Commercial Officer | 23 Şubat 2023 A | 13.538 | 0 | 0 | $0 |
| Bradford W Smith | Chief Financial and Business Officer and Treasurer | 23 Şubat 2023 A | 14.219 | 0 | 0 | $0 |
| Gabriel Cohn | Chief Medical Officer | 01 Ocak 2022 M | 2.629 | 0 | 0 | $0 |
| Diyong Xu | Yönetim kurulu üyesi | 12 Haziran 2026 A | 625.000 | 2 | 0 | $15.000.000 |
| David S. Grayzel | Yönetim kurulu üyesi | 12 Haziran 2026 A | · | 0 | 0 | $0 |
| Sven Ante Lundberg | Yönetim kurulu üyesi | 12 Haziran 2026 A | · | 0 | 0 | $0 |
| Isaac Manke | Yönetim kurulu üyesi | 12 Haziran 2026 A | 53.521 | 0 | 0 | $0 |
| Arthur Tzianabos | Yönetim kurulu üyesi | 12 Haziran 2026 A | 7.983 | 0 | 0 | $0 |
| Mark T Iwicki | Yönetim kurulu üyesi | 12 Haziran 2026 A | · | 0 | 0 | $0 |
| Mary Thistle | Yönetim kurulu üyesi | 12 Haziran 2026 A | · | 0 | 0 | $0 |
| Kathleen Laporte | Yönetim kurulu üyesi | 12 Haziran 2026 A | · | 0 | 0 | $0 |
| Jeffrey V. Poulton | Yönetim kurulu üyesi | 14 Haziran 2023 A | · | 0 | 0 | $0 |
| Alise Reicin | Yönetim kurulu üyesi | 14 Haziran 2023 A | · | 0 | 0 | $0 |
| Matthew R Patterson | Yönetim kurulu üyesi | 14 Haziran 2023 A | · | 0 | 0 | $0 |
| Steven Gillis | Yönetim kurulu üyesi | 14 Haziran 2023 A | 6.068.695 | 0 | 0 | $0 |
| Kush Parmar | Yönetim kurulu üyesi | 15 Haziran 2022 A | 181.435 | 0 | 0 | $0 |
| Richard J. Gregory | Yönetim kurulu üyesi | 15 Haziran 2022 A | 10.806 | 0 | 0 | $0 |
| Cameron Wheeler | Yönetim kurulu üyesi | 06 Haziran 2019 A | · | 0 | 0 | $0 |
| Mahendra Shah | Yönetim kurulu üyesi | 02 Nisan 2018 A | 909.742 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 5 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,29% | 8.018 SH | 02 Ekim 2026 | Günlük |
| IWC · iShares Trust | 0,02% | 29.271 SH | 11 Eylül 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,00% | 14.652 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 119.269 SH | 19 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 389.115 SH | 19 Ağustos 2026 | Günlük |
QTTB Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 12 analist
AL
Medyan hedef
$36.00
+337,4%
3 25,0%
Güçlü Al
8 66,7%
Al
1 8,3%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
5 analist · 2026-09-29Ortalama hedef $39.60 +381,2%
← Tüm hedeflerin altında
Mevcut fiyat $8.23
Düşük$29.00
Ortalama$39.60
Yüksek$59.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| QTTB | $43M | 1.4 | · | 55.5% | 200.3% | · |
| PALI | $375M | -7.8 | · | · | -25.4% | · |
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | · |
| CAMP | $318M | -2.3 | 436.5% | -2298.5% | -183.4% | · |
| EVMN | $540M | -1.5 | 85.7% | -529.8% | -401.2% | · |
| GLSI | $300M | -14.7 | · | · | -2159.7% | · |
| IVVD | $697M | -8.2 | 110.5% | -98.2% | -36.9% | · |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | · |
| MGNX | $102M | -1.4 | -0.31% | -49.9% | -87.0% | · |
| LYEL | $654M | -1.9 | -41.0% | -762355.6% | -100.3% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 5, 2026